Có báo cáo - Madrid tổ chức bàn tròn EAPM về Nông học khối u, đổi mới, RWE và Chẩn đoán phân tử diễn ra tại Đại hội ESMO, 2020

The Brussels-based European Alliance for Personalised Medicine (EAPM) has held a key round table at the ESMO Congress in Madrid. Báo cáo có sẵn bằng cách nhấp vào Ở đây, Giám đốc Điều hành EAPM Denis Horgan viết.

The high-level discussions under the banner ‘EAPM seeks innovative solutions at ESMO for cancer patients’ held virtually in the Spanish capital, represented the eight such roundtables conducted by the Alliance at the Congress.   This type of interaction is one key aspect of EAPM’s stated goals - to engage with the medical community whenever possible, and at every level.

The round table comes at a crucial time as Europe deploys new efforts to bring innovation into healthcare systems and to establish strategic co-operation. EAPM is actively engaged in discussions with stakeholders and with policymakers on the emerging Beating Cancer Plan and the CancerMission, the promised EU health Data Space, the review of research incentives in its orphan drug rules, the overarching Pharmaceutical Strategy scheduled to appear before the end of 2020, and the new determination– announced in mid-September - to go beyond the draft EU4 Health programme and create a genuine European Health Union.

Attendees at the round table included patients, European Parliament politicians, European Medicine Agency, public health experts, economists, industry representatives from ICT and pharma-ceutical companies, and other specialists from across multiple disciplines.

GIÁO DỤC: EAPM’s multi-stakeholder, high-diversity meeting took into account the fact that new discoveries - generated from a deeper understanding of the human genome.  This shift is rapidly progressing in oncology but is slower in other areas. And, while there are many barriers to innova-tion in clinical practice - including market access, scientific, and/or regulatory challenges - the big-gest challenge across the healthcare system is continuing medical education for healthcare professionals. Báo cáo có sẵn bằng cách nhấp vào Ở đây. 

MOLECULAR DIAGNOSTICS, INCENTIVES AND MORE:  Topics discussed in depth were incentives and molecular diagnostics which were underpinned by our recent academic publication entitled: Bringing Greater Accuracy to Europe’s Health -care Systems: The Unexploited Potential of Biomarker Testing in Oncology, đã giành được nhiều lời khen ngợi, và nó có thể được đọc Ở đây.   T took into account the ongoing developments in the field of personalised medicine, such as DNA profiling, concepts of ‘va-lue’ and biomarkers and, because of the diversity of the disciplines of the delegates attending, the meeting constituted a bridge between new developments and those that will implement them, as well as the patients who will eventually benefit.

A CHANGING SOCIETY, WITH CHANGING NEEDS: As we all know, a key difference between personalised medicine and conventional methods of treating patients is the setting aside of a ‘one-size-fits-all’ philosophy in favour of a much more targeted process.   A major reason for this is the fact that patients respond differently to the same medicine being used to treat the ‘same’ disease.

quảng cáo

Cancer patients overall have a non-response rate of a massive 75 percent. This is for a disease that is the biggest healthcare cost burden of all, as well as being the biggest killer.  Meanwhile, sickness and disability costs form a large portion of GDP and government social spending while overall healthcare costs are rising all the time with Europe’s ageing population. Indeed, the average lifespan has increased by around 25 years in the space of a century.  Better adoption of molecular Diagnostic and early diagnosis can ensure a better rational allocation of resources in society to tackle this societal burden.

INNOVATION IS KEY: Tumour Agnostics and RWE

Tất nhiên, một trụ cột chính trong việc đưa các loại thuốc mới, nhắm mục tiêu đến bệnh nhân là sự đổi mới. Điều này, trong lĩnh vực sức khỏe, có nghĩa là dịch thuật kiến ​​thức và hiểu biết sâu sắc về cái mà chúng ta có thể gọi là "giá trị". Và giá trị đó bao gồm giá trị cho bệnh nhân nhưng cũng phải tính đến giá trị cho các hệ thống chăm sóc sức khỏe, xã hội và tất nhiên là các nhà sản xuất. 

In the context of tumour agnostics, fittingly described by many speakers as a paradigm shift in cancer care,  tumour agnostic therapies present a new promise of precision medicine – and accordingly, as was frequently argued during the discussion, they require a new way of thinking about cancer care. They offer new opportunities for patients with rare mutations, and the pipeline of potential tumour agnostic therapies/ indications is growing rapidly.  

For the RWE evidence session, the discussion made clear that the simplicity of the concept of using RWE in healthcare belies the many complexities underlying its exploitation. Harnessing health data from many sources in real time should help faster and better medical decision-making. But it will not happen automatically, as the roundtable made clear

For each of the three round tables, the report includes recommendations.  Here is that link to the report again bằng cách nhấp chuột Ở đây. 

Chia sẻ bài viết này: